Prostate Cancer

Health written question – answered on 27th March 2012.

Alert me about debates like this

Photo of Jonathan Reynolds Jonathan Reynolds Labour, Stalybridge and Hyde

To ask the Secretary of State for Health if he will provide an update on the status of the prostate cancer drug Abiraterone.

Photo of Paul Burstow Paul Burstow The Minister of State, Department of Health

Abiraterone (Zytiga) is licensed for the treatment of metastatic prostrate cancer and there are no national restrictions on its prescribing in the national health service.

The National Institute for Health and Clinical Excellence (NICE) is currently appraising abiraterone for two separate indications. NICE is an independent body and has not yet issued final guidance to the national health service on either indication.

In the absence of final positive NICE technology appraisal guidance, primary care trusts (PCTs) are required to take funding decisions locally based on an assessment of the available evidence and to have processes in place to consider individual funding requests for drugs. Where a cancer drug is not routinely funded by a PCT, patients may be able to access it through the Cancer Drugs Fund.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.